Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2023 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding

EDISON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
January 05, 2023 16:15 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023

EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
December 05, 2022 16:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

EDISON, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
December 05, 2022 09:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial

– Hepion Enrolls 60 F3 NASH Subjects in only 12 weeks, facilitated by AGILE 3+ non-invasive test – – Hepion, Summit Clinical Research, and HepQuant Align to Deliver Rencofilstat’s Hepatic Function...
November 07, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Present Rencofilstat’s Poly-Indication Potential at the 6th Annual Antifibrotic Drug Development Summit

EDISON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
November 04, 2022 08:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock

EDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
November 02, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022

EDISON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
October 26, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION’ Clinical Trial Results

- Study met safety, tolerability, and pharmacokinetics primary endpoints - - Reductions in ALT, ProC3, and C6M suggest direct antifibrotic effects with longer treatment duration - - Enrollment...
October 20, 2022 16:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
October 19, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Participate in the ThinkEquity Conference

EDISON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right